<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7191905</article-id><article-id pub-id-type="pmid">32321320</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1755670</article-id><article-id pub-id-type="publisher-id">1755670</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Synthesis and biological evaluation of new 3(2<italic>H</italic>)-pyridazinone derivatives as non-toxic anti-proliferative compounds against human colon carcinoma HCT116 cells</article-title><alt-title alt-title-type="running-authors">Z. &#x000d6;zdemir et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>&#x000d6;zdemir</surname><given-names>Zeynep</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Utku</surname><given-names>Semra</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mathew</surname><given-names>Bijo</given-names></name><xref ref-type="aff" rid="AF0003"><sup>c</sup></xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8698-9440</contrib-id><name><surname>Carradori</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="AF0004"><sup>d</sup></xref><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><name><surname>Orlando</surname><given-names>Giustino</given-names></name><xref ref-type="aff" rid="AF0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Di Simone</surname><given-names>Simonetta</given-names></name><xref ref-type="aff" rid="AF0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alag&#x000f6;z</surname><given-names>Mehmet Abdullah</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>&#x000d6;z&#x000e7;elik</surname><given-names>Azime Berna</given-names></name><xref ref-type="aff" rid="AF0005"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uysal</surname><given-names>Mehtap</given-names></name><xref ref-type="aff" rid="AF0005"><sup>e</sup></xref><xref ref-type="aff" rid="AF0006"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferrante</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="AF0004"><sup>d</sup></xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutical Chemistry, &#x00130;n&#x000f6;n&#x000fc; University</institution>, Malatya, <country>Turkey</country>; </aff><aff id="AF0002"><label>b</label><institution>Department of Pharmaceutical Chemistry, Mersin University</institution>, Mersin, <country>Turkey</country>; </aff><aff id="AF0003"><label>c</label><institution>Department of Pharmaceutical Chemistry, Division of Drug Design and Medicinal Chemistry Research Lab, Ahalia School of Pharmacy</institution>, Palakkad, <country>India</country>; </aff><aff id="AF0004"><label>d</label><institution>Department of Pharmacy, &#x0201c;G. d&#x02019;Annunzio&#x0201d; University of Chieti-Pescara</institution>, Chieti, <country>Italy</country>; </aff><aff id="AF0005"><label>e</label><institution>Department of Pharmaceutical Chemistry, Gazi University</institution>, Ankara, <country>Turkey</country>; </aff><aff id="AF0006"><label>f</label><institution>Department of Pharmaceutical Chemistry, Erzincan Binali Y&#x00131;ld&#x00131;r&#x00131;m University</institution>, Erzincan, <country>Turkey</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Simone Carradori <email>simone.carradori@unich.it</email><institution>Department of Pharmacy, &#x0201c;G. d&#x02019;Annunzio&#x0201d; University of Chieti-Pescara</institution>, Chieti 66100, <country>Italy</country>; </corresp><corresp id="AN0002">Bijo Mathew <email>bijovilaventgu@gmail.com</email>, <email>bijo.mathew@ahalia.ac.in</email><institution>Department of Pharmaceutical Chemistry, Division of Drug Design and Medicinal Chemistry Research Lab, Ahalia School of Pharmacy</institution>, Palakkad 678557, Kerala, <country>India</country>.</corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>4</month><year>2020</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="106">1100</fpage><lpage>1109</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>08</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1755670.pdf"/><abstract><title>Abstract</title><p>Novel 3(2<italic>H</italic>)-pyridazinone derivatives were designed, synthesised in satisfactory yields and evaluated in different experimental assays to assess their preliminary toxicity <italic>in&#x000a0;vivo</italic> and anti-proliferative effects against HCT116 cell lines <italic>in&#x000a0;vitro</italic>. <italic>Artemia salina</italic> lethality test provided LC<sub>50</sub> values &#x0003e;100&#x02009;&#x000b5;g/mL for all compounds. Successive assays revealed that some compounds were endowed with a promising anti-proliferative effect against HCT116 cells, alone or stimulated by serotonin as a pro-inflammatory factor in order to mimick an inflamed model <italic>in&#x000a0;vivo</italic> of cancer cell microenvironment. Moreover, the kinurenic acid level after treatment with these newly synthesised compounds was monitored as a marker of anti-proliferation in colon carcinoma models. The IC<sub>50</sub> values obtained for the best-in-class compounds were comparable to that of daunorubicin as a reference drug. Conversely, these compounds were not able to counteract the spontaneous migration of human cancer HCT116 cell line in the wound healing paradigm.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Serotonin</kwd><kwd>anti-proliferative agents</kwd><kwd>pyridazinone</kwd><kwd>kynurenic acid</kwd><kwd>HCT116</kwd><kwd>wound healing</kwd><kwd><italic>Artemia salina</italic> lethality test</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">Ministero Italiano dell&#x02019;Universit&#x000e0; e della Ricerca (MIUR)</named-content><named-content content-type="funderidentifier">10.13039/501100003407</named-content></funding-source></award-group><funding-statement>This work was supported by intramural grants by Ministero Italiano dell&#x02019;Universit&#x000e0; e della Ricerca (MIUR) FAR 2019 (ex 60%), held by Dr. Simone Carradori.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="10"/><word-count count="6417"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><p>Cancer consists of an uncontrolled proliferation of cells in different tissues and organs; it is a disease whose clinical appearance, treatment and approach are different from each other. Cancer is a major global health problem and it is currently the second leading cause of death in the world being expected to surpass cardiovascular diseases in the next few years<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Many factors, from bacteria to viruses, from radiation to heredity, from environmental factors to nutritional habits and chemicals, are accused of cancer formation. In the data announced by the World Health Organisation (WHO), approximately 18 million people were diagnosed with cancer in 2018, and around 10 million people died from cancer. According to data of Global Cancer Obervatory (GLOBOCAN), the most common types are lung (2.1 million), breast (2.09 million), colorectal (1.8 million), prostate (1.3 million), stomach (1 million) cancer. According to cancer-related deaths, lung (1.8 million), colorectal (881 thousand), stomach (783 thousand), liver (782 thousand) and breast (627 thousand) are listed. Colorectal carcinomas (CRC) are one of the most common types of cancer in the world that cause death. CRC metastases account for 40&#x02013;50% of recently diagnosed cases and are correlated with high morbidity<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>.</p><p>In medicinal chemistry pyridazinones have been the subject of intensive synthetic investigations, because they possess a wide spectrum of pharmacological activities and gained importance in recent years<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. A number of compounds such as zardaverine/imidazole, bemoradan, indolindan, pimobendan are examples of pyridazinones that are biologically active. Literature survey revealed that substituted pyridazinones have reported to possess pharmacological activities, which can be rationalised in the SAR study reported in <xref ref-type="fig" rid="F0001">Figure 1</xref>
<xref rid="CIT0006" ref-type="bibr"><sup>6&#x02013;12</sup></xref>. There are also compounds which were shown to have anti-cancer or cytostatic activity in the literature against HEP3B (liver cancer cells), HCT116 (colon cancer cells), SH-SY5Y (neuroblastoma cells) and promising selectivity index with respect to human fibroblasts<xref rid="CIT0013" ref-type="bibr"><sup>13&#x02013;16</sup></xref>. These results suggest that pyridazinone compounds may be useful in cancer chemotherapy, depending on the type of cancer, and that derivatives bearing different substituents may exhibit varying degrees of cytotoxic effect.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Structure-activity relationships (SARs) within the 3(2<italic>H</italic>)-pyridazinone derivatives reported in the literature.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1755670_F0001_B"/></fig><p>Pursuing our efforts to discover novel anti-cancer compounds<xref rid="CIT0017" ref-type="bibr"><sup>17&#x02013;19</sup></xref> and with the aim of enlarging the SAR knowledge within this chemical scaffold, we designed fifteen new 3(2<italic>H</italic>)-pyridazinones investigating the anti-proliferative effects against the human HCT116 cell line, their toxicity in the <italic>Artemia salina</italic> lethality assay <italic>in&#x000a0;vivo</italic>, the HCT116 viability after serotonin challenging and compound treatment, the release of kynurenic acid after compound treatment and, lastly, the capability to limit the spontaneous migration of HCT116 cells in the wound healing paradigm.</p></sec><sec id="s0002"><label>2.</label><title>Experimental protocols</title><p>The fine chemicals and all solvents used in this study were purchased locally from Merck (Darmstadt, Germany) and Aldrich Chemical Co. (Steinheim, Germany).</p><sec id="s0003"><label>2.1.</label><title>Chemical studies</title><p>Melting points of the compounds were determined on Electrothermal 9200 melting points apparatus (Southent, Great Britain) and the values given are uncorrected. The IR spectra of the compounds were recorded on a Bruker Vector 22 IR Spectrophotometer (Bruker Analytische Messtechnik, Karlsruhe, Germany). The <sup>1</sup>H-NMR and 13C-NMR spectra of the compounds were recorded on a Bruker 400&#x02009;MHz-NMR Spectrometer (Rheinstetten, Karlsruhe, Germany) using tetramethylsilane as an internal standard. All the chemical shifts were recorded as <italic>&#x003b4;</italic> (ppm). The mass spectra (HRMS) of the compounds were recorded on Waters Acquity Ultra Performance Liquid Chromatograpy Micromass which combined LCT PremierTM XE UPLC/MS TOFF spectrophotometer (Waters Corp, Milford, USA) by ESI&#x02009;+ and ESI&#x02013; techniques.</p><sec id="s0004"><label>2.1.1.</label><title>Synthesis of 4-(3-fluoro-4-methoxyphenyl)-4-oxobutanoic acid (I)</title><p>A mixture of 0.275&#x02009;mol aluminium chloride, 20&#x02009;mL carbon disulphide and 0.25&#x02009;mol succinic anhydride was added portionwise in standard conditions to a mixture of 0.25&#x02009;mol 2-fluoroanisole and 50&#x02009;mL of carbon disulphide. Then, the mixture was refluxed for 4&#x02009;h at 40&#x02013;50&#x02009;&#x000b0;C. After cooling, the residue was poured onto ice water and the precipitate was collected, dried and recrystallized from water. M.P.: 164&#x02009;&#x000b0;C. (Lit: M.P. 168&#x02009;&#x000b0;C). Yield: 78%, C<sub>11</sub>H<sub>12</sub>FO<sub>4</sub> Calcd.: 226.0720, Found: 227.0724. NMR spectra are in accordance with literature data.</p></sec><sec id="s0005"><label>2.1.2.</label><title>Synthesis of 6-(3-fluoro-4-methoxyphenyl)-4,5-dihydro-3(2H)-pyridazinone (II)</title><p>0.01&#x02009;Mol of 4-(3-fluoro-4-methoxyphenyl)-4-oxobutanoic acid and 0.015&#x02009;mol of hydrazine hydrate (0.85&#x02009;mL; 55%) in 30&#x02009;mL of ethanol were refluxed for 4&#x02009;h. The reaction mixture was cooled and the precipitate thus formed was collected by filtration, dried, crystallised from ethanol. M.P.: 182&#x02009;&#x000b0;C. (Lit: M.P. 180&#x02013;182&#x02009;&#x000b0;C). Yield: 58%, C<sub>11</sub>H<sub>12</sub>FN<sub>2</sub>O<sub>2</sub> Calcd.: 223.2270. Found: 223.2854. NMR spectra are in accordance with literature data.</p></sec><sec id="s0006"><label>2.1.3.</label><title>Synthesis of 6-(3-fluoro-4-methoxyphenyl)-3(2H)-pyridazinone (III)</title><p>A solution of 0.043&#x02009;mol of bromine in 25&#x02009;mL of glacial acetic acid was added dropwise to a solution of 0.039&#x02009;mol of 6-(3-fluoro-4-methoxyphenyl)-4,5-dihydro-3(2<italic>H</italic>)-pyridazinone (<bold>II</bold>) in 100&#x02009;mL of glacial acetic acid at 60&#x02013;70&#x02009;&#x000b0;C. Then, the reaction mixture was refluxed for 3&#x02009;h. After cooling to 5&#x02009;&#x000b0;C, it was poured into ice water and converted to free base with ammonium hydroxide. The precipitate was collected by filtration, washed with cold water until neutral, dried, and crystallised from ethanol-water mixture. M.P.: 221&#x02009;&#x000b0;C. (Lit: M.P. 220&#x02013;222&#x02009;&#x000b0;C). Yield: 76%, C<sub>11</sub>H<sub>10</sub>FN<sub>2</sub>O<sub>2</sub> Calcd.: 221.0726, Found: 221.0721. NMR spectra are in accordance with literature data.</p></sec><sec id="s0007"><label>2.1.4.</label><title>Synthesis of ethyl 6-(3-fluoro-4-methoxyphenyl)-3(2H)-pyridazinone-2-yl-acetate (IV)</title><p>A mixture of required 6-substituted-3(2<italic>H</italic>)-pyridazinones (<bold>III</bold>) (0.01&#x02009;mol), ethyl 3-bromo-acetate (0.02&#x02009;mol) and potassium carbonate (0.02&#x02009;mol) in acetone (40&#x02009;mL) was refluxed overnight. After the mixture was cooled, the organic salts were filtered off, the solvent evaporated, and the residue was purified by recrystallization from ethanol to give the ester. M.P.: 126&#x02009;&#x000b0;C. Yield: 69%, C<sub>15</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>4</sub> Calcd.: 307.1094, Found: 307.1074. <sup>1</sup>H-NMR (400&#x02009;MHz) (DMSO-d<sub>6</sub>): <italic>&#x003b4;</italic> 8.09 (d, 1H, pyridazinone H<sub>5</sub>), 7.05&#x02013;7.82 (m, 3H, phenyl H<sub>2</sub>, H<sub>5</sub>, H<sub>6</sub>), 7.31 (t, 1H, pyridazinone H<sub>4</sub>), 4.88 (s, 2H, <underline>CH<sub>2</sub></underline>COOCH<sub>2</sub>CH<sub>3</sub>), 4.10 (q, 2H, CH<underline><sub>2</sub></underline>COO<underline>CH<sub>2</sub></underline>CH<sub>3</sub>), 3.91 (s, 3H, OCH<sub>3</sub>), 1.22 (t, 3H, CH<sub>2</sub>COOCH<sub>2</sub><underline>CH<sub>3</sub></underline>).</p></sec><sec id="s0008"><label>2.1.5.</label><title>Synthesis of 6-(3-fluoro-4-methoxyphenyl)-3(2H)-pyridazinone-2-yl-acetohydrazide (V)</title><p>To the ethanolic solution of ethyl 6-substituted-3(2<italic>H</italic>)-pyridazinone-2-yl-acetate (<bold>IV</bold>) (25&#x02009;mL, 0.01&#x02009;mol) hydrazine hydrate (99%) (3&#x02009;mL) was added and stirred for 3&#x02009;h at room temperature. The obtained precipitate was filtered off, washed with water, dried and recrystallized from ethanol. M.P.: 206&#x02009;&#x000b0;C. Yield: 76%, C<sub>13</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub> Calcd.: 293.1050, Found: 293.1060.</p></sec><sec id="s0009"><label>2.1.6.</label><title>Synthesis of substituted/nonsubstituted benzalhydrazone derivatives of 6-(3-fluoro-4-methoxyphenyl)-3(2H)-pyridazinone-2-yl-acetohydrazide (via-o)</title><p>A mixture of 6-(3-fluoro-4-methoxyphenyl)-3(2<italic>H</italic>)-pyridazinone-2-yl-acetohydrazide <bold>V</bold> (0.01&#x02009;mol) and appropriate benzaldehyde (0.01&#x02009;mol) was refluxed in ethanol (15&#x02009;mL) for 6&#x02009;h. Then, the mixture was poured into ice water. The formed precipitate was recrystallized from the appropriate solvent. The compounds were identified by IR, <sup>1</sup>H-NMR, 13C-NMR and mass spectra. All spectral data of the compounds were in accordance with the assigned structures as shown below.</p><sec id="s0010"><label>2.1.6.1.</label><title>N&#x02019;-benzylidene-2-(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIa)</title><p>White crystals; yield: 80%; M.P.: 132&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1698 (C=O; hydrazone), 1648 (C=O; pyridazinone ring), 1587 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.30 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.09 (1H; d; pyridazinone H<sup>5</sup>), 7.27 (1H; d; pyridazinone H<sup>4</sup>), 7.11&#x02013;8.14 (8H; m; phenyl protons), 8.24 (1H; s; &#x02013;N=CH&#x02013;), 11.76 (1H; s; &#x02013;NH&#x02013;N). 13C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.9 (1C; CH<sub>3</sub>O), 56.7 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; =CH), 113.8 (1C; pyridazinone C<sup>5</sup>), 114.5 (1C; phenyl C<sup>4</sup>), 127.3 (2C; phenyl C<sup>3,</sup>5), 129.1 (2C; phenyl C<sup>2,6</sup>), 134.3 (1C; pyridazinone C<sup>4</sup>), 142.8 (2C; 3-fluoro-4-methoxyphenyl C<sup>2,6</sup>), 144.5 (1C; phenyl C<sup>1</sup>), 147.6 (2C; 3-fluoro-4-methoxyphenyl C<sup>3,5</sup>), 148.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 151.2 (1C; pyridazinone C<sup>6</sup>), 159.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.5 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.2 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 381.1348, Found: <italic>m</italic>/<italic>z</italic> 381.1348 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0011"><label>2.1.6.2.</label><title>N&#x02019;-(4-fluorobenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIb)</title><p>White crystals; yield: 83%; M.P.: 238&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1693 (C=O; hydrazone), 1652 (C=O; pyridazinone ring), 1514 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.30 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.08 (1H; d; pyridazinone H<sup>5</sup>), 7.11 (1H; d; pyridazinone H<sup>4</sup>), 7.27&#x02013;7.82 (7H; m; phenyl protons), 8.10 (1H; s; &#x02013;N=CH&#x02013;), 11.76 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.7 (1C; CH<sub>3</sub>O), 56.7 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; =CH), 113.6 (1C; pyridazinone C<sup>5</sup>), 114.3 (2C; 4-fluorophenyl C<sup>3,5</sup>), 116.3 (2C; 4-fluorophenyl C<sup>2,6</sup>), 127.5 (1C; pyridazinone C<sup>4</sup>), 129.5 (2C; 3-fluoro-4-methoxyphenyl C<sup>2,6</sup>), 129.6 (1C; 4-fluorophenyl C<sup>1</sup>), 131.4 (2C; 3-fluoro-4-methoxyphenyl C<sup>3,5</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 148.6 (1C; pyridazinone C<sup>6</sup>), 152.9 (1C; 4-fluorophenyl C<sup>4</sup>), 159.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 164.3 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.3 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>17</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 399.1269, Found: <italic>m</italic>/<italic>z</italic> 399.1285 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0012"><label>2.1.6.3.</label><title>N&#x02019;-(4-trifluoromethylbenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIc)</title><p>White crystals; yield: 84%; M.P.: 252&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1704 (C=O; hydrazone), 1699 (C=O; pyridazinone ring), 1587 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.33 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.10 (1H; d; pyridazinone H<sup>5</sup>), 7.26 (1H; d; pyridazinone H<sup>4</sup>), 7.12&#x02013;7.97 (7H; m; phenyl protons), 8.14 (1H; s; &#x02013;N=CH&#x02013;), 11.96 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.9 (1C; CH<sub>3</sub>O), 56.7 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; CF<sub>3</sub>), 113.6 (1C; =CH), 114.3 (1C; pyridazinone C<sup>5</sup>), 114.5 (2C; 4-fluorophenyl C<sup>3,5</sup>), 126.0 (2C; 4-fluorophenyl C<sup>2,6</sup>), 127.5 (1C; pyridazinone C<sup>4</sup>), 128.1 (2C; 3-fluoro-4-methoxyphenyl C<sup>2,6</sup>), 131.4 (1C; 4-fluorophenyl C<sup>1</sup>), 138.3 (2C; 3-fluoro-4-methoxyphenyl C<sup>3,5</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 151.2 (1C; pyridazinone C<sup>6</sup>), 152.9 (1C; 4-fluorophenyl C<sup>4</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.8 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.5 (1C; pyridazinone C<sup>3</sup>); C<sub>21</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 449.1237, Found: <italic>m</italic>/<italic>z</italic> 449.1237 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0013"><label>2.1.6.4.</label><title>N&#x02019;-(2-fluorobenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VId)</title><p>White crystals; yield: 68%; M.P.: 222&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1696 (C=O; hydrazone), 1676 (C=O; pyridazinone ring), 1596 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.87 (3H; s; CH<sub>3</sub>O), 5.34 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.09 (1H; d; pyridazinone H<sup>5</sup>), 7.12 (1H; d; pyridazinone H<sup>4</sup>), 7.10&#x02013;8.26 (7H; m; phenyl protons), 8.40 (1H; s; &#x02013;N=CH&#x02013;), 12.00 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.9 (1C; CH<sub>3</sub>O), 56.6 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.5 (1C; CF<sub>3</sub>), 113.7 (1C; =CH), 114.4 (1C; pyridazinone C<sup>5</sup>), 127.4 (1C; 2-trifluoromethylphenyl C<sup>5</sup>), 130.0 (1C; 2-trifluoromethylphenyl C<sup>4</sup>), 130.5 (1C; 2-trifluoromethylphenyl C<sup>6</sup>), 132.2 (1C; 2-trifluoromethylphenyl C<sup>3</sup>), 133.3 (1C; pyridazinone C<sup>4</sup>), 139.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 142.7 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 142.9 (1C; 2-trifluoromethylphenyl C<sup>1</sup>), 148.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 148.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 151.2 (1C; 2-trifluoromethylphenyl C<sup>2</sup>), 152.9 (1C; pyridazinone C<sup>6</sup>), 159.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.8 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.5 (1C; pyridazinone C<sup>3</sup>); C<sub>21</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 449.1237, Found: <italic>m</italic>/<italic>z</italic> 449.1258 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0014"><label>2.1.6.5.</label><title>N&#x02019;-(2-methylbenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIe)</title><p>White crystals; yield: 96%; M.P.: 210&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1700 (C=O; hydrazone), 1640 (C=O; pyridazinone ring), 1588 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 2.45 (3H; s; CH<sub>3</sub>), 3.90 (3H; s; CH<sub>3</sub>O), 5.29 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.08 (1H; d; pyridazinone H<sup>5</sup>), 7.11 (1H; d; pyridazinone H<sup>4</sup>), 7.09&#x02013;8.13 (7H; m; phenyl protons), 8.31 (1H; s; &#x02013;N=CH&#x02013;), 11.69 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 20.1 (1C; CH<sub>3</sub>), 53.9 (1C; CH<sub>3</sub>O), 56.5 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.6 (1C; =CH), 114.3 (1C; pyridazinone C<sup>5</sup>), 126.5 (1C; 2-methylphenyl C<sup>5</sup>), 126.6 (1C; 2-methylphenyl C<sup>4</sup>), 127.1 (1C; 2-methylphenyl C<sup>6</sup>), 130.0 (1C; 2-methylphenyl C<sup>3</sup>), 131.3 (1C; pyridazinone C<sup>4</sup>), 131.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 132.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 137.1 (1C; 2-methylphenyl C<sup>1</sup>), 142.8 (1C; 2-methylphenyl C<sup>2</sup>), 143.9 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 151.2 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 152.9 (1C; pyridazinone C<sup>6</sup>), 159.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.4 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.1 (1C; pyridazinone C<sup>3</sup>); C<sub>21</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 449.1237, Found: <italic>m</italic>/<italic>z</italic> 449.1258 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0015"><label>2.1.6.6.</label><title>N&#x02019;-(2-methoxybenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIf)</title><p>White crystals; yield: 80%; M.P.: 214&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1693 (C=O; hydrazone), 1649 (C=O; pyridazinone ring), 1589 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.86 (3H; s; CH<sub>3</sub>O), 3.90 (3H; s; CH<sub>3</sub>O), 5.29 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.00 (1H; d; pyridazinone H<sup>5</sup>), 7.09 (1H; d; pyridazinone H<sup>4</sup>), 7.08&#x02013;8.13 (7H; m; phenyl protons), 8.38 (1H; s; &#x02013;N=CH&#x02013;), 11.71 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.9 (2C; CH<sub>3</sub>O), 56.7 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.6 (1C; =CH), 114.5 (1C; pyridazinone C<sup>5</sup>), 121.1 (1C; 2-methoxyphenyl C<sup>5</sup>), 122.3 (1C; 2-methoxyphenyl C<sup>4</sup>), 126.0 (1C; 2-methoxyphenyl C<sup>6</sup>), 127.5 (1C; 2-methoxyphenyl C<sup>3</sup>), 131.4 (1C; pyridazinone C<sup>4</sup>), 132.1 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 140.1 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 140.2 (1C; 2-methoxyphenyl C<sup>1</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 148.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 151.2 (1C; 2-methoxyphenyl C<sup>2</sup>), 152.9 (1C; pyridazinone C<sup>6</sup>), 158.1 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 159.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 159.4 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.1 (1C; pyridazinone C<sup>3</sup>); C<sub>21</sub>H<sub>20</sub>FN<sub>4</sub>O<sub>4</sub> MS (ESI+) Calcd.: 411.1469, Found: <italic>m</italic>/<italic>z</italic> 411.1468 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0016"><label>2.1.6.7.</label><title>N&#x02019;-(4-methylbenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIg)</title><p>White crystals; yield: 74%; M.P.: 220&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1696 (C=O; hydrazone), 1656 (C=O; pyridazinone ring), 1586 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 2.34 (3H; s; CH<sub>3</sub>), 3.90 (3H; s; CH<sub>3</sub>O), 5.28 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.07 (1H; d; pyridazinone H<sup>5</sup>), 7.10 (1H; d; pyridazinone H<sup>4</sup>), 7.08&#x02013;8.10 (7H; m; phenyl protons), 8.13 (1H; s; &#x02013;N=CH&#x02013;), 11.69 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 20.1 (1C; CH<sub>3</sub>), 53.9 (1C; CH<sub>3</sub>O), 56.5 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.6 (1C; =CH), 114.3 (1C; pyridazinone C<sup>5</sup>), 126.5 (1C; 4-methylphenyl C<sup>5</sup>), 126.6 (1C; 4-methylphenyl C<sup>4</sup>), 127.1 (1C; 4-methylphenyl C<sup>6</sup>), 130.0 (1C; 4-methylphenyl C<sup>3</sup>), 131.3 (1C; pyridazinone C<sup>4</sup>), 131.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 132.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 137.1 (1C; 4-methylphenyl C<sup>1</sup>), 142.8 (1C; 4-methylphenyl C<sup>2</sup>), 143.9 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 151.2 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 152.9 (1C; pyridazinone C<sup>6</sup>), 159.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.4 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.1 (1C; pyridazinone C<sup>3</sup>); C<sub>21</sub>H<sub>20</sub>FN<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 395.1519, Found: <italic>m</italic>/<italic>z</italic> 395.1513 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0017"><label>2.1.6.8.</label><title>N&#x02019;-(4-methoxybenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIh)</title><p>White crystals; yield: 85%; M.P.: 207&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1687 (C=O; hydrazone), 1662 (C=O; pyridazinone ring), 1599 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.81 (3H; s; CH<sub>3</sub>O), 3.90 (3H; s; CH<sub>3</sub>O), 5.28 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.00 (1H; d; pyridazinone H<sup>5</sup>), 7.02 (1H; d; pyridazinone H<sup>4</sup>), 7.03&#x02013;7.98 (7H; m; phenyl protons), 8.11 (1H; s; &#x02013;N=CH&#x02013;), 11.63 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.9 (1C; CH<sub>3</sub>O), 54.1 (1C; CH<sub>3</sub>O), 56.7 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; =CH), 113.6 (1C; pyridazinone C<sup>5</sup>), 113.6 (1C; 4-methoxyphenyl C<sup>3</sup>), 113.8 (1C; 4-methoxyphenyl C<sup>5</sup>), 114.3 (1C; 4-methoxyphenyl C<sup>2</sup>), 114.5 (1C; 4-methoxyphenyl C<sup>6</sup>), 126.9 (1C; pyridazinone C<sup>4</sup>), 127.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 127.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 129.1 (1C; 4-methoxyphenyl C<sup>1</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 144.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 152.9 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 159.3 (1C; pyridazinone C<sup>6</sup>), 159.4 (1C; 4-methoxyphenyl C<sup>4</sup>), 161.2 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.2 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.0 (1C; pyridazinone C<sup>3</sup>); C<sub>21</sub>H<sub>20</sub>FN<sub>4</sub>O<sub>4</sub> MS (ESI+) Calcd.: 411.1469, Found: <italic>m</italic>/<italic>z</italic> 411.1483 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0018"><label>2.1.6.9.</label><title>N&#x02019;-(4-nitrobenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIi)</title><p>White crystals; yield: 38%; M.P.: 265&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1705 (C=O; hydrazone), 1647 (C=O; pyridazinone ring), 1581 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.35 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.10 (1H; d; pyridazinone H<sup>5</sup>), 7.26 (1H; d; pyridazinone H<sup>4</sup>), 7.12&#x02013;8.29 (7H; m; phenyl protons), 8.31 (1H; s; &#x02013;N=CH&#x02013;), 12.06 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.8 (1C; CH<sub>3</sub>O), 56.4 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; =CH), 113.6 (1C; pyridazinone C<sup>5</sup>), 113.7 (1C; 4-nitrophenyl C<sup>3</sup>), 114.3 (1C; 4-nitrophenyl C<sup>5</sup>), 124.4 (1C; 4-nitrophenyl C<sup>2</sup>), 124.4 (1C; 4-nitrophenyl C<sup>6</sup>), 127.5 (1C; pyridazinone C<sup>4</sup>), 128.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 130.0 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 140.6 (1C; 4-nitrophenyl C<sup>1</sup>), 142.9 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 148.2 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 151.2 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 152.8 (1C; pyridazinone C<sup>6</sup>), 159.3 (1C; 4-nitrophenyl C<sup>4</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 164.0 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.7 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>5</sub> MS (ESI+) Calcd.: 426.1214, Found: <italic>m</italic>/<italic>z</italic> 426.1205 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0019"><label>2.1.6.10.</label><title>N&#x02019;-(4-isopropylbenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIj)</title><p>White crystals; yield: 71%; M.P.: 164&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1700 (C=O; hydrazone), 1656 (C=O; pyridazinone ring), 1584 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 1.21 (6H; d; CH<sub>3</sub>), 2.90&#x02013;2.95 (1H; q; &#x02013;CH&#x02013;), 3.90 (3H; s; CH<sub>3</sub>O), 5.28 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.09 (1H; d; pyridazinone H<sup>5</sup>), 7.26 (1H; d; pyridazinone H<sup>4</sup>), 7.11&#x02013;8.13 (7H; m; phenyl protons), 8.20 (1H; s; &#x02013;N=CH&#x02013;), 11.71 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 24.1 (2C; CH<sub>3</sub>), 39.6 (1C; CH), 53.9 (1C; CH<sub>3</sub>O), 56.5 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 114.4 (1C; =CH), 127.1 (1C; pyridazinone C<sup>5</sup>), 127.2 (2C; 4-isopropylphenyl C<sup>3,</sup>5), 127.3 (1C; 4-isopropylphenyl C<sup>4</sup>), 127.4 (2C; 4-isopropylphenyl C<sup>2,</sup>6), 127.5 (1C; pyridazinone C<sup>4</sup>), 132.1 (2C; 3-fluoro-4-methoxyphenyl C<sup>5,</sup>6), 142.8 (1C; 4-isopropylphenyl C<sup>1</sup>), 144.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 148.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 151.1 (1C; pyridazinone C<sup>6</sup>), 152.9 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 159.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 159.4 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.1 (1C; pyridazinone C<sup>3</sup>); C<sub>23</sub>H<sub>23</sub>FN<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 423.1832, Found: <italic>m</italic>/<italic>z</italic> 423.1817 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0020"><label>2.1.6.11.</label><title>N&#x02019;-(2-bromobenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIk)</title><p>White crystals; yield: 89%; M.P.: 189&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1705 (C=O; hydrazone), 1667 (C=O; pyridazinone ring), 1588 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.89 (3H; s; CH<sub>3</sub>O), 5.32 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.09 (1H; d; pyridazinone H<sup>5</sup>), 7.27 (1H; d; pyridazinone H<sup>4</sup>), 7.37&#x02013;8.38 (7H; m; phenyl protons), 8.58 (1H; s; &#x02013;N=CH&#x02013;), 11.95 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.9 (1C; CH<sub>3</sub>O), 56.6 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.6 (1C; =CH), 114.3 (1C; pyridazinone C<sup>5</sup>), 123.8 (1C; 2-bromophenyl C<sup>5</sup>), 127.5 (1C; 2-bromophenyl C<sup>3</sup>), 128.4 (1C; 2-bromophenyl C<sup>4</sup>), 130.0 (1C; 2-bromophenyl C<sup>6</sup>), 131.4 (1C; pyridazinone C<sup>4</sup>), 132.2 (2C; 3-fluoro-4-methoxyphenyl C<sup>2,6</sup>), 133.1 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 133.5 (1C; 2-bromophenyl C<sup>1</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 148.6 (1C; 2-bromophenyl C<sup>2</sup>), 151.2 (2C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>, pyridazinone C<sup>6</sup>), 152.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 159.4 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.4 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>16</sub>BrFN<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 459.0468, Found: <italic>m</italic>/<italic>z</italic> 459.0467 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0021"><label>2.1.6.12.</label><title>N&#x02019;-(2-fluorobenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIl)</title><p>White crystals; yield: 72%; M.P.: 224&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1689 (C=O; hydrazone), 1648 (C=O; pyridazinone ring), 1585 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.31 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.09 (1H; d; pyridazinone H<sup>5</sup>), 7.11 (1H; d; pyridazinone H<sup>4</sup>), 7.26&#x02013;8.13 (7H; m; phenyl protons), 8.46 (1H; s; &#x02013;N=CH&#x02013;), 11.87 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.7 (1C; CH<sub>3</sub>O), 56.4 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; =CH), 113.6 (1C; pyridazinone C<sup>5</sup>), 114.3 (1C; 2-fluorophenyl C<sup>5</sup>), 116.3 (1C; 2-fluorophenyl C<sup>3</sup>), 121.9 (1C; 2-bromophenyl C<sup>4</sup>), 126.9 (1C; 2-fluorophenyl C<sup>6</sup>), 127.6 (1C; pyridazinone C<sup>4</sup>), 131.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 137.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 148.6 (1C; 2-fluorophenyl C<sup>1</sup>), 151.2 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 152.9 (1C; 2-fluorophenyl C<sup>2</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 160.3 (1C; pyridazinone C<sup>6</sup>), 161.9 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.6 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.4 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 399.1269, Found: <italic>m</italic>/<italic>z</italic> 399.1257 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0022"><label>2.1.6.13.</label><title>N&#x02019;-(4-bromobenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIm)</title><p>White crystals; yield: 69%; M.P.: 256&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1701 (C=O; hydrazone), 1651 (C=O; pyridazinone ring), 1584 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.30 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.09 (1H; d; pyridazinone H<sup>5</sup>), 7.26 (1H; d; pyridazinone H<sup>4</sup>), 7.11&#x02013;8.11 (7H; m; phenyl protons), 8.21 (1H; s; &#x02013;N=CH&#x02013;), 11.82 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.9 (1C; CH<sub>3</sub>O), 56.4 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; =CH), 113.8 (1C; pyridazinone C<sup>5</sup>), 114.3 (1C; 4-bromophenyl C<sup>3</sup>), 114.5 (1C; 4-bromophenyl C<sup>5</sup>), 123.7 (1C; 4-bromophenyl C<sup>2</sup>), 127.5 (1C; 4-bromophenyl C<sup>6</sup>), 129.4 (1C; pyridazinone C<sup>4</sup>), 131.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 132.3 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 133.6 (1C; 4-bromophenyl C<sup>1</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 143.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 148.5 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 151.2 (1C; pyridazinone C<sup>6</sup>), 152.9 (1C; 4-bromophenyl C<sup>4</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.6 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.3 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>16</sub>BrFN<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 459.0468, Found: <italic>m</italic>/<italic>z</italic> 459.0446 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0023"><label>2.1.6.14.</label><title>N&#x02019;-(4-hydroxybenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIn)</title><p>White crystals; yield: 42%; M.P.: 251&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1683 (C=O; hydrazone), 1653 (C=O; pyridazinone ring), 1581 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.25 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 6.81 (1H; d; pyridazinone H<sup>5</sup>), 6.83 (1H; d; pyridazinone H<sup>4</sup>), 7.08&#x02013;8.12 (7H; m; phenyl protons), 9.92 (1H; s; &#x02013;N=CH&#x02013;), 11.55 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.8 (1C; CH<sub>3</sub>O), 56.5 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.5 (1C; =CH), 113.7 (1C; pyridazinone C<sup>5</sup>), 114.4 (1C; 4-hydroxyphenyl C<sup>3</sup>), 116.1 (1C; 4-hydroxyphenyl C<sup>5</sup>), 116.1 (1C; 4-hydroxyphenyl C<sup>2</sup>), 122.9 (1C; 4-hydroxyphenyl C<sup>6</sup>), 125.4 (1C; pyridazinone C<sup>4</sup>), 127.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 129.1 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 131.3 (1C; 4-hydroxyphenyl C<sup>1</sup>), 142.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 144.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 148.5 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 151.2 (1C; pyridazinone C<sup>6</sup>), 152.9 (1C; 4-hydroxyphenyl C<sup>4</sup>), 159.8 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 159.9 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 167.9 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>4</sub> MS (ESI+) Calcd.: 397.1312, Found: <italic>m</italic>/<italic>z</italic> 397.1309 (M<sup>+</sup>; 100.0%).</p></sec><sec id="s0024"><label>2.1.6.15.</label><title>N&#x02019;-(2,4-dichlorobenzylidene)-2&#x02013;(3-(3-fluoro-4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl)acetohydrazide (VIo)</title><p>White crystals; yield: 91%; M.P.: 229&#x02009;&#x000b0;C; IR (&#x003bd; cm<sup>&#x02212;1</sup>, ATR): 1705 (C=O; hydrazone), 1645 (C=O; pyridazinone ring), 1582 (C=N); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 3.90 (3H; s; CH<sub>3</sub>O), 5.32 (2H; s; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 7.08 (1H; d; pyridazinone H<sup>5</sup>), 7.11 (1H; d; pyridazinone H<sup>4</sup>), 7.10&#x02013;8.13 (6H; m; phenyl protons), 8.35 (1H; s; &#x02013;N=CH&#x02013;), 11.98 (1H; s; &#x02013;NH&#x02013;N); <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz): <italic>&#x003b4;</italic> 53.7 (1C; CH<sub>3</sub>O), 56.7 (1C; &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;C=O), 113.4 (1C; =CH), 113.5 (1C; pyridazinone C<sup>5</sup>), 113.7 (1C; 4-chlorophenyl C<sup>3</sup>), 114.4 (1C; 4-chlorophenyl C<sup>5</sup>), 129.9 (1C; 4-chlorophenyl C<sup>6</sup>), 130.7 (1C; pyridazinone C<sup>4</sup>), 131.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>2</sup>), 134.1 (1C; 3-fluoro-4-methoxyphenyl C<sup>6</sup>), 135.5 (1C; 4-chlorophenyl C<sup>1</sup>), 139.5 (1C; 3-fluoro-4-methoxyphenyl C<sup>5</sup>), 142.9 (1C; 3-fluoro-4-methoxyphenyl C<sup>1</sup>), 148.6 (1C; 3-fluoro-4-methoxyphenyl C<sup>3</sup>), 151.2 (1C; pyridazinone C<sup>6</sup>), 152.8 (1C; 4-chlorophenyl C<sup>2</sup>), 159.3 (1C; 4-chlorophenyl C<sup>4</sup>), 159.4 (1C; 3-fluoro-4-methoxyphenyl C<sup>4</sup>), 163.7 (1C; CH<sub>2</sub>&#x02013;N&#x02013;C=O), 168.5 (1C; pyridazinone C<sup>3</sup>); C<sub>20</sub>H<sub>15</sub>Cl<sub>2</sub>FN<sub>4</sub>O<sub>3</sub> MS (ESI+) Calcd.: 449.0583, Found: <italic>m</italic>/<italic>z</italic> 449.0574 (M<sup>+</sup>; 100.0%).</p></sec></sec></sec><sec id="s0025"><label>2.2.</label><title>Pharmacology</title><sec id="s0026"><label>2.2.1.</label><title>Artemia salina lethality test in&#x000a0;vivo</title><p>In <italic>Artemia salina</italic> lethality bioassay, brine shrimp larvae were incubated for 24&#x02009;h with compounds <bold>VIa</bold>-<bold>o</bold> (0.01&#x02013;10&#x02009;mg/mL) dissolved in the incubation medium (artificial sea water). The detailed protocol was described in our previous article<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>.</p></sec><sec id="s0027"><label>2.2.2.</label><title>Human colon cancer HCT116 cell culture and experiments in&#x000a0;vitro</title><p>HCT116 cell line (ATCC&#x000ae; CCL-247&#x02122;) was cultured in DMEM (Euroclone) supplemented with 10% (<italic>v</italic>/<italic>v</italic>) heat-inactivated foetal bovine serum and 1.2% (<italic>v</italic>/<italic>v</italic>) penicillin G/streptomycin in 75&#x02009;cm<sup>2</sup> tissue culture flask (<italic>n</italic>=5 individual culture flasks for each condition) as previously reported with or without serotonin treatment<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>.</p><p>In the same condition, the kynurenic acid (KA) extracellular level was determined through a validated high performance liquid chromatography (HPLC)-fluorimetric method<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. To assess the cytotoxicity of synthesised compounds (<bold>VIa&#x02013;o</bold>), a viability assay was performed on 96 microwell plates, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. Cells were incubated with compounds (10&#x02009;&#x000b5;g/mL) for 24&#x02009;h. An aliquot of 10&#x02009;&#x000b5;L of MTT (5&#x02009;mg/mL) was added to each well and incubated for 3&#x02009;h. The viability of HCT116 cell line was evaluated both in basal conditions and after challenging with serotonin (5-HT) at 1&#x02009;ng/mL. The anti-proliferative effects were compared to that induced by daunorubicin (0.1&#x02013;20&#x02009;&#x000b5;g/mL), used as reference drug.</p><p>Finally, the effects of the most potent compounds were evaluated on the spontaneous migration of HCT116 cells, in the 48&#x02009;h following the experimental lesion of cell monolayer (wound healing paradigm). The detailed protocol related to wound healing experimental model was described in our previous article<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>.</p></sec><sec id="s0028"><label>2.2.3.</label><title>Statistical analysis</title><p>Results of <italic>in&#x000a0;vitro</italic> studies were expressed as means&#x02009;&#x000b1;&#x02009;standard error (SE) of three experiments performed in triplicate. Statistical analysis was determined through analysis of variance (ANOVA), followed by <italic>post hoc</italic> Newman-Keuls comparison multiple test. The level of significance was set at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec></sec><sec id="s0029"><label>3.</label><title>Results and discussion</title><p>In order to enlarge our SAR on this chemical scaffold, we investigated the presence of different substituents on the hydrazone moiety to explore the chemical space in terms of electronic and steric effects. Moreover, we deleted the piperazine linker attached to the pyridazinone core nucleus aiming at limiting the conformational freedom of our compounds. The title compounds (<bold>VIa&#x02013;o</bold>) were synthesised according to the literature methods as outlined in <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of compounds <bold>VIa-o</bold>. Reagents and conditions: (i) AlCl<sub>3</sub>, CS<sub>2</sub>; (ii) H<sub>2</sub>NNH<sub>2</sub>, EtOH, reflux (6&#x02009;h); (iii) Br<sub>2</sub>, CH<sub>3</sub>COOH, reflux (overnight); (iv) BrCH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux (overnight); (v) H<sub>2</sub>NNH<sub>2</sub><sup>.</sup>H<sub>2</sub>O, MeOH, rt; (vi) EtOH, reflux (6&#x02009;h), nonsubstituted/substitutedbenzaldehyde.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1755670_SCH0001_B"/></fig><p>Synthesis of the compounds was initiated by obtaining benzoyl propanoic acid derivative (<bold>I</bold>) in the presence of succinic anhydride and 2-fluoroanisole by anhydrous aluminium chloride catalysis. Subsequently, the reaction of this compound with hydrazine hydrate led to the formation of 4,5-dihydro-3(<italic>2H</italic>)-pyridazinone (<bold>II</bold>). 6-Substituted-3(<italic>2H</italic>)-pyridazinone derivative (<bold>III</bold>) was obtained by oxidation of <bold>II</bold> with bromine in glacial acetic acid. Ethyl 6-substituted-3(<italic>2H</italic>)-pyridazinone-2-ylacetate derivative (<bold>IV</bold>) was obtained by the reaction of <bold>III</bold> with ethyl bromoacetate in the presence of K<sub>2</sub>CO<sub>3</sub> in acetone. Then, 6-substituted-3(<italic>2H</italic>)-pyridazinone-2-ylacetohydrazide derivative (<bold>V</bold>) was synthesised by the condensation reaction of <bold>IV</bold> with hydrazine hydrate. Ultimately, the title compounds bearing benzylidenhydrazide structure were obtained by the reaction of <bold>V</bold> with substituted/nonsubstituted benzaldehydes. All of the title compounds were reported for the first time in this study. The reaction yields ranged approximately from 38% to 96%. Compound <bold>VIe</bold> was synthesised with the highest yield (96%), while compound <bold>VIi</bold> with the lowest yield (38%). The physical and spectral properties of the starting compounds were in accordance with the literature. Molecular structures of title compounds were confirmed by IR, <sup>1</sup>H-NMR, <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C-NMR, and mass spectral data. Their molecular structures, yields, and melting points are given in <xref rid="t0001" ref-type="table">Table 1</xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Molecular structures, yields and melting points of <bold>VIa&#x02013;o</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="5" align="left"><inline-graphic xlink:href="IENZ_A_1755670_ILG0001_B.gif" content-type="black-white"/><hr/></th></tr><tr><th align="left">Compound</th><th align="center"><italic>R</italic><sub>1</sub></th><th align="center"><italic>R</italic><sub>2</sub></th><th align="center">Yield (%)</th><th align="center">mp (&#x000b0;C)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>VIa</bold></td><td align="left">H</td><td align="left">H</td><td align="char" char=".">80</td><td align="char" char=".">132</td></tr><tr><td align="left"><bold>VIb</bold></td><td align="left">H</td><td align="left">F</td><td align="char" char=".">83</td><td align="char" char=".">238</td></tr><tr><td align="left"><bold>VIc</bold></td><td align="left">H</td><td align="left">CF<sub>3</sub></td><td align="char" char=".">84</td><td align="char" char=".">252</td></tr><tr><td align="left"><bold>VId</bold></td><td align="left">CF<sub>3</sub></td><td align="left">H</td><td align="char" char=".">68</td><td align="char" char=".">222</td></tr><tr><td align="left"><bold>VIe</bold></td><td align="left">CH<sub>3</sub></td><td align="left">H</td><td align="char" char=".">96</td><td align="char" char=".">210</td></tr><tr><td align="left"><bold>VIf</bold></td><td align="left">OCH<sub>3</sub></td><td align="left">H</td><td align="char" char=".">80</td><td align="char" char=".">214</td></tr><tr><td align="left"><bold>VIg</bold></td><td align="left">H</td><td align="left">CH<sub>3</sub></td><td align="char" char=".">74</td><td align="char" char=".">220</td></tr><tr><td align="left"><bold>VIh</bold></td><td align="left">H</td><td align="left">OCH<sub>3</sub></td><td align="char" char=".">85</td><td align="char" char=".">207</td></tr><tr><td align="left"><bold>VIi</bold></td><td align="left">H</td><td align="left">NO<sub>2</sub></td><td align="char" char=".">38</td><td align="char" char=".">265</td></tr><tr><td align="left"><bold>VIj</bold></td><td align="left">H</td><td align="left"><italic>i</italic>-C<sub>3</sub>H<sub>7</sub></td><td align="char" char=".">71</td><td align="char" char=".">164</td></tr><tr><td align="left"><bold>VIk</bold></td><td align="left">Br</td><td align="left">H</td><td align="char" char=".">89</td><td align="char" char=".">189</td></tr><tr><td align="left"><bold>VIl</bold></td><td align="left">F</td><td align="left">H</td><td align="char" char=".">72</td><td align="char" char=".">224</td></tr><tr><td align="left"><bold>VIm</bold></td><td align="left">H</td><td align="left">Br</td><td align="char" char=".">69</td><td align="char" char=".">256</td></tr><tr><td align="left"><bold>VIn</bold></td><td align="left">H</td><td align="left">OH</td><td align="char" char=".">42</td><td align="char" char=".">251</td></tr><tr><td align="left"><bold>VIo</bold></td><td align="left">Cl</td><td align="left">Cl</td><td align="char" char=".">91</td><td align="char" char=".">229</td></tr></tbody></table></table-wrap><p>Firstly, the biocompatibility limit of the compounds was determined through the <italic>A. salina</italic> brine shrimp lethality test <italic>in&#x000a0;vivo</italic>. The nauplii were stimulated with compounds <bold>VIa</bold>&#x02013;<bold>o</bold>, in the range 0.01&#x02013;10&#x02009;mg/mL. The lethality test showed LC<sub>50</sub> values &#x0003e;100&#x02009;&#x000b5;g/mL for all the compounds. Based on our previous investigations<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>, a 10-fold lower concentration (10&#x02009;&#x000b5;g/mL) was selected for the subsequent <italic>in&#x000a0;vitro</italic> cell-based tests. In this regard, the human colon cancer HCT116 cell line was selected and treated with the aforementioned molecules. The HCT116 viability was stimulated through 5-HT challenging. 5-HT has long been described as a pro-inflammatory factor, particularly in the gut<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>, with <italic>in&#x000a0;vitro</italic> studies substantiating a mitogen role, mediated by different receptor types towards multiple cell lines<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>. According to these findings, a preliminary study was carried out in order to optimise the experimental conditions that could demonstrate a cell viability-stimulating effect of 5-HT, in a wide range of concentrations (10&#x02009;pg/mL &#x02013; 1&#x02009;&#x000b5;g/mL). We observed that HCT116 cell viability increased in a concentration-dependent manner, in the range 0.1&#x02013;1&#x02009;&#x000b5;g/mL, although it remained constant, at upper tested concentrations (<xref ref-type="fig" rid="F0002">Figure 2</xref>) given. Considering our previous <italic>ex vivo</italic> and <italic>in&#x000a0;vitro</italic> studies focussed on inflamed colon specimens and hypothalamic cells, respectively, reporting 5-HT concentrations in the order of 1&#x02009;ng/mL<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>, we have chosen the 5-HT concentration of 1&#x02009;ng/mL as a reliable proliferative stimulus for the following tests. Specifically, compounds <bold>VIc</bold>&#x02013;<bold>e</bold> and <bold>VIh</bold>&#x02013;<bold>m</bold> were able to inhibit 5-HT-stimulated viability of HCT116 cells (<xref ref-type="fig" rid="F0003">Figure 3</xref>), thus substantiating the potential anti-proliferative effect of the compounds in the real <italic>in&#x000a0;vivo</italic> colon cancer cell microenvironment, characterised by the up-regulated production of multiple pro-inflammatory and anti-apoptotic/mitogen factors, including 5-HT<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Effects of serotonin (5-HT) in the range 10&#x02009;pg/mL &#x02212; 1&#x02009;&#x000b5;g/mL on colon cancer HCT116 cell viability (MTT test). Data are means&#x02009;&#x000b1;&#x02009;SE and analysed through analysis of variance (ANOVA), followed by <italic>post hoc</italic> Newman-Keuls test. ANOVA, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; <italic>post hoc</italic>, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. CTR (control) group.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1755670_F0002_B"/></fig><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Effects of compounds <bold>VIa</bold>&#x02013;<bold>o</bold> at 10&#x02009;&#x000b5;g/mL on serotonin (5-HT)-induced colon cancer HCT116 cell viability (MTT test). Data are means&#x02009;&#x000b1;&#x02009;SE and analysed through analysis of variance (ANOVA), followed by <italic>post hoc</italic> Newman-Keuls test. ANOVA, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; <italic>post hoc</italic>, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. 5-HT (serotonin) group.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1755670_F0003_B"/></fig><p>Furthermore, compounds were assayed for evaluating modulatory effects on the extracellular level of KA, one of the two main kynurenine metabolites. Kynurenic acid was reported to be produced in multiple tissues, including brain and peripheral organs<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>, although pharmacokinetic studies excluded any possibility of the peripheral pool to cross blood-brain barrier<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>. In the brain, the kynurenine-derived kynurenic acid was described as a reliable marker of neuroprotection<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>, whereas it seems to be involved in inflammatory response at the peripheral level<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>. Kynurenic acid was also described as an anti-proliferative factor towards colon, renal, and glioma cells<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>. Specifically, this marker was considered as a potential chemopreventive agent against colon cancer<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>. The assessment of KA levels showed that the sole compound <bold>VIc</bold> was able to blunt 5-HT-induced KA depletion (<xref ref-type="fig" rid="F0004">Figure 4</xref>) after treatment. Additionally, the KA level after compound <bold>VIc</bold> stimulation was even higher compared to basal condition (CTR group). Conversely, the other tested compounds (<bold>VIa</bold>, <bold>VIb</bold> and <bold>VId</bold>&#x02013;<bold>m</bold>) failed to prevent the inhibition of KA level following the stimulation with 5-HT. They were able in potentiating 5-HT-induced KA depletion, as well. The results of this pharmacological screening suggest a minor role exerted by the compounds <bold>VIa</bold>, <bold>VIb</bold> and <bold>VId&#x02013;m</bold> as anti-proliferative agents.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Effects of compounds <bold>VIa&#x02013;o</bold> at 10&#x02009;&#x000b5;g/mL on serotonin (5-HT)-induced reduction of kynurenic acid (KA) release from colon cancer HCT116 cells. Data are means&#x02009;&#x000b1;&#x02009;SE and analysed through analysis of variance (ANOVA), followed by <italic>post hoc</italic> Newman-Keuls test. ANOVA, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; <italic>post hoc</italic>, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. 5-HT (serotonin) group.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1755670_F0004_B"/></fig><p>Considering the effects induced by all compounds on HCT116 viability and KA production, compounds <bold>VIc</bold>, <bold>VIe</bold> and <bold>VIk</bold> were further assayed in order to deepen our knowledge about their anti-proliferative effects, in basal conditions. Specifically, HCT116 cells were stimulated with the aforementioned compounds, in a wider concentration range (0.1&#x02013;20&#x02009;&#x000b5;g/mL), with respect to the initial test. Additionally, the anti-proliferative effects induced by these compounds were compared with that of daunorubicin, used as anti-tumoral reference drug in the same concentration range. The IC<sub>50</sub> values were calculated and, as evidenced in <xref ref-type="fig" rid="F0005">Figure 5(A&#x02013;D)</xref>, compounds <bold>VIe</bold> and <bold>VIk</bold> showed interesting potencies (<xref ref-type="fig" rid="F0005">Figure 5(C,D)</xref>) with IC<sub>50</sub> values of 3.09 and 2.73&#x02009;&#x000b5;g/mL respectively, that were very close to that shown by daunorubicin (1.39&#x02009;&#x000b5;g/mL). Conversely, compound <bold>VIc</bold> showed an IC<sub>50</sub> value (15.03&#x02009;&#x000b5;g/mL) that was at least 10-fold higher compared to daunorubicin (<xref ref-type="fig" rid="F0005">Figure 5(A,B)</xref>). On the other hand, although the MTT test seems to exclude any application of <bold>VIc</bold> compound as anti-proliferative agent, the increased KA level (<xref ref-type="fig" rid="F0004">Figure 4</xref>), shown at a concentration even lower than the IC<sub>50</sub>, indicated a potential use as chemopreventive agent that deserves a further investigation.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Effects of compounds <bold>VIc</bold>, <bold>VIe</bold>, <bold>VIk</bold> and daunorubicin at 0.1&#x02013;20&#x02009;&#x000b5;g/mL on HCT116 cell viability. Data are means&#x02009;&#x000b1;&#x02009;SE and analysed through analysis of variance (ANOVA), followed by <italic>post hoc</italic> Newman-Keuls test. ANOVA, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; <italic>post hoc</italic>, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs CTR (control) group.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1755670_F0005_B"/></fig><p>Finally, considering their potencies in reducing HCT116 cell viability, compounds <bold>VIe</bold> and <bold>VIk</bold> were further studied in order to evaluate their effects on the spontaneous migration of HCT116 cells, through the wound healing paradigm. In this experiment, HCT116 cells were treated with compounds <bold>VIe</bold> and <bold>VIk</bold> at their respective IC<sub>50</sub> values. The spontaneous migration of HCT116 cells was monitored in the 48&#x02009;h following the experimental lesion of cell monolayer. The null effects on sponstaneous migration (<xref ref-type="fig" rid="F0006">Figure 6</xref>) rule out any involvement of the tested compounds in altering the invasion capacity of human colon cancer cells.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Effects of compounds <bold>VIe</bold> (3.09&#x02009;&#x000b5;g/mL) and <bold>VIk</bold> (2.73&#x02009;&#x000b5;g/mL) on the spontaneous migration of human colon cancer HCT116 cell line (wound healing paradigm). The spontaneous migration was monitored in the 48&#x02009;h following treatment. Data are expressed as percentage scratch area relative to the untreated CTR group.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1755670_F0006_B"/></fig></sec><sec id="s0030"><label>4.</label><title>Conclusion</title><p>Fifteen new 3(2<italic>H</italic>)-pyridazinone derivatives were synthesised and studied for their ability to limit the proliferation of HCT116 cell line (colon carcinoma), alone or after stimulation with serotonin, a well-recognized pro-inflamamtory factor in the gut. In particular, compound <bold>VIc</bold> induced a strong release of kynurenic acid after treatment, thus representing a strong chemopreventive agent in this model. Moreover, all compounds resulted non-toxic up to 100&#x02009;&#x000b5;g/mL in the <italic>A. salina</italic> lethality assay, whereas three of them (<bold>VIc</bold>, <bold>VIe</bold> and <bold>VIk</bold>) displayed a promising inhibitory action comparable to that of daunorubicin as a standard drug at basal conditions.</p></sec></body><back><sec id="s0031"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogelstein</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kinzler</surname><given-names>KW</given-names></name></person-group>
<article-title>The multistep nature of cancer</article-title>. <source>Trends Genet</source>
<year>1993</year>;<volume>9</volume>:<fpage>38</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">8384385</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening</article-title>. <source>CA Cancer J Clin</source>
<year>2019</year>;<volume>69</volume>:<fpage>184</fpage>&#x02013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">30875085</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Colombet</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods</article-title>. <source>Int J Cancer</source>
<year>2019</year>;<volume>144</volume>:<fpage>1941</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">30350310</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group>
<article-title>Cancer statistics, 2020</article-title>. <source>CA Cancer J Clin</source>
<year>2020</year>;<volume>70</volume>:<fpage>7</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">31912902</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>PS</given-names></name></person-group>
<article-title>Various biological activities of pyridazinone ring derivatives</article-title>. <source>Asian J Chem</source>
<year>2011</year>;<volume>23</volume>:<fpage>1905</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamali</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ozan</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Kahya</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of some 3(2<italic>H</italic>)-pyridazinone and 1(<italic>2H</italic>)-phthalazinone derivatives incorporating aminothiazole moiety and investigation of their antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitory activities</article-title>. <source>Med Chem Res</source>
<year>2015</year>;<volume>24</volume>:<fpage>1210</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Utku</surname><given-names>S</given-names></name>, <name name-style="western"><surname>G&#x000f6;k&#x000e7;e</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aslan</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and in&#x000a0;vitro antimycobacterial activities of novel 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(substituted/nonsubstituted acetophenone)hydrazone</article-title>. <source>Turk J Chem</source>
<year>2011</year>;<volume>61</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#x0015e;ahina</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Bad&#x00131;&#x000e7;oglu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>G&#x000f6;k&#x000e7;e</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and analgesic and antiinflammatory activity of methyl[6-substituted-3(2H)-pyridazinone-2-yl]acetate derivatives</article-title>. <source>Arch Pharm Pharm Med</source>
<year>2004</year>;<volume>337</volume>:<fpage>445</fpage>&#x02013;<lpage>52</lpage>.</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shaharyar</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Triazole incorporated pyridazinones as a new class of antihypertensive agents: design, synthesis and in&#x000a0;vivo screening</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>1023</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">21211966</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shaharyar</surname><given-names>M</given-names></name></person-group>
<article-title>Synthesis, characterization and antihypertensive activity of pyridazinone derivatives</article-title>. <source>Eur J Med Chem</source>
<year>2010</year>;<volume>45</volume>:<fpage>2283</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">20189270</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#x000d6;z&#x000e7;elik</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>&#x000d6;zdemir</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Sari</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new series of pyridazinone derivatives as cholinesterases inhibitors: synthesis, in&#x000a0;vitro activity and molecular modeling studies</article-title>. <source>Pharmacol Rep</source>
<year>2019</year>;<volume>71</volume>:<fpage>1253</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">31675671</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagle</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pawar</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sonawane</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Docking simulation, synthesis and biological evaluation of novel pyridazinone containing thymol as potential antimicrobial agents</article-title>. <source>Med Chem Res</source>
<year>2014</year>;<volume>23</volume>:<fpage>918</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Log&#x000e9;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tauzia</surname><given-names>ML</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K&#x003b1; inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2012</year>;<volume>57</volume>:<fpage>225</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">23063566</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#x000d6;zdemir</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Ba&#x0015f;ak-T&#x000fc;rkmen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ayhan</surname><given-names>&#x00130;</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of new 6-[4-(2-fluorophenylpiperazine-1-yl)]-3(2H)-pyridazinone-2-acethyl-2-(substitutedbenzal)hydrazone derivatives and evulation of their cytotoxic effects in liver and colon cancer cell line</article-title>. <source>Pharm Chem J</source>
<year>2019</year>;<volume>52</volume>:<fpage>923</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#x000c7;ift&#x000e7;i</surname><given-names>O</given-names></name>, <name name-style="western"><surname>&#x000d6;zdemir</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Acar</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The novel synthesized pyridazinone derivates had the antiproliferative and apoptotic effects in SHSY5Y and HEP3B cancer cell line</article-title>. <source>Lett Org Chem</source>
<year>2018</year>;<volume>15</volume>:<fpage>323</fpage>&#x02013;<lpage>31</lpage>.</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rathish</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Javed</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones</article-title>. <source>Eur J Med Chem</source>
<year>2012</year>;<volume>49</volume>:<fpage>304</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22305543</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marconi</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ricci</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Kinesin Eg5 targeting inhibitors as a new strategy for gastric adenocarcinoma treatment</article-title>. <source>Molecules</source>
<year>2019</year>;<volume>24</volume>:<fpage>3948</fpage>.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marconi</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Gallorini</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The up-regulation of oxidative stress as a potential mechanism of novel MAO-B inhibitors for glioblastoma treatment</article-title>. <source>Molecules</source>
<year>2019</year>;<volume>24</volume>:<fpage>2005</fpage>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuchuk</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Tuccitto</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Citterio</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma</article-title>. <source>Oncoimmunology</source>
<year>2018</year>;<volume>7</volume>:<fpage>e1445452</fpage>.<pub-id pub-id-type="pmid">29900055</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrante</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Recinella</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ronci</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Multiple pharmacognostic characterization on hemp commercial cultivars: focus on inflorescence water extract activity</article-title>. <source>Food Chem Toxicol</source>
<year>2019</year>;<volume>125</volume>:<fpage>452</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">30711720</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Giacomo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Chiavaroli</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Orlando</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Neuroprotective and neuromodulatory effects induced by cannabidiol and cannabigerol in rat Hypo-E22 cells and isolated hypothalamus</article-title>. <source>Antioxidants</source>
<year>2020</year>;<volume>9</volume>:<fpage>71</fpage>.</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regmi</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Ku</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JA</given-names></name></person-group>
<article-title>Serotonin regulates innate immune responses of colon epithelial cells through Nox2-derived reactive oxygen species</article-title>. <source>Free Radic Biol Med</source>
<year>2014</year>;<volume>69</volume>:<fpage>377</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">24524998</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rivas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Belmont</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability</article-title>. <source>Mol Clin Oncol</source>
<year>2018</year>;<volume>9</volume>:<fpage>243</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">30155245</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Seymour</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mothersill</surname><given-names>CE</given-names></name></person-group>
<article-title>Cell line-specific direct irradiation and bystander responses are influenced by fetal bovine serum serotonin concentrations</article-title>. <source>Radiat Res</source>
<year>2018</year>;<volume>190</volume>:<fpage>262</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">29963973</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Shyu</surname><given-names>RY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tazarotene-induced gene 1 inhibits prostaglandin E2-stimulated HCT116 colon cancer cell growth</article-title>. <source>J Biomed Sci</source>
<year>2011</year>;<volume>18</volume>:<fpage>88</fpage>.<pub-id pub-id-type="pmid">22126303</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notarangelo</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Beggiato</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schwarcz</surname><given-names>R</given-names></name></person-group>
<article-title>Assessment of prenatal kynurenine metabolism using tissue slices: focus on the neosynthesis of kynurenic acid in mice</article-title>. <source>Dev Neurosci</source>
<year>2019</year>;<volume>41</volume>:<fpage>102</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">31117076</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukui</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schwarcz</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rapoport</surname><given-names>SI</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Blood&#x02013;brain barrier transport of kynurenines: implications for brain synthesis and metabolism</article-title>. <source>J Neurochem</source>
<year>1991</year>;<volume>56</volume>:<fpage>2007</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">1827495</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddison</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Giorgini</surname><given-names>F</given-names></name></person-group>
<article-title>The kynurenine pathway and neurodegenerative disease</article-title>. <source>Semin Cell Dev Biol</source>
<year>2015</year>;<volume>40</volume>:<fpage>134</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">25773161</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ol&#x000e1;h</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Her&#x000e9;di</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Menyh&#x000e1;rt</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability</article-title>. <source>Drug Des Devel Ther</source>
<year>2013</year>;<volume>7</volume>:<fpage>981</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciniak</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wnorowski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Smoli&#x00144;ska</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Kynurenic acid protects against thioacetamide-induced liver injury in rats</article-title>. <source>Anal Cell Pathol (Amst)</source>
<year>2018</year>;<volume>2018</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walczak</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Deneka-Hannemann</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jarosz</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells</article-title>. <source>Pharmacol Rep</source>
<year>2014</year>;<volume>66</volume>:<fpage>130</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">24905318</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walczak</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Turski</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Rajtar</surname><given-names>G</given-names></name></person-group>
<article-title>Kynurenic acid inhibits colon cancer proliferation in&#x000a0;vitro: effects on signaling pathways</article-title>. <source>Amino Acids</source>
<year>2014</year>;<volume>46</volume>:<fpage>2393</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">25012123</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walczak</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Turski</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Rzeski</surname><given-names>W</given-names></name></person-group>
<article-title>Kynurenic acid enhances expression of p21 Waf1/Cip1 in colon cancer HT-29 cells</article-title>. <source>Pharmacol Rep</source>
<year>2012</year>;<volume>64</volume>:<fpage>745</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">22814028</pub-id></mixed-citation></ref></ref-list></back></article>